comparemela.com

Latest Breaking News On - ஜீன் ஞானஸ்நானம் டி சாட்டிலன் - Page 1 : comparemela.com

Sanofi (SNY) Q2 2021 Earnings Call Transcript

Sanofi (SNY) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

Sanofi SA (SNY) Q1 2021 Earnings Call Transcript

Sanofi SA (SNY) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Sanofi SA (NASDAQ: SNY) [Audio begins abruptly] Sanofi s First Quarter 2021 Earnings Call. I would now like to turn the call over to Eva Schaefer-Jansen, Head of Sanofi Investor Relations. Please go ahead, Eva.SPONSORED: 10 stocks we like better than Sanofi When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.   David and Tom just revealed what they believe are the ten best stocks for investors to buy right now. and Sanofi wasn t one of them! That s right they think these 10 stocks are even better buys.

Sanofi (SNY) Q4 2020 Earnings Call Transcript

Operator Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi Fourth Quarter 2020 Earnings Call and Virtual Capital Markets Day. We have planned for a 15-minute break between both events. You may remain connected to the Zoom link for all sessions. I would now like to turn the call over to Eva Schaefer-Jansen, Head of Sanofi Investor Relations. Please go ahead, Eva. Eva Schaefer-Jansen Head of Investor Relations Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi s 2020 fourth quarter results, followed by a dedicated Q&A session. In about an hour, we will begin our virtual Capital Markets Day presentation and discussion. As usual, you can find the slides to both sessions on the Investors page of our website at sanofi.com.

Sanofi eyes more cost cuts to boost profitability

French drugmaker Sanofi pledged more cost cuts to increase margins as it relies ever more on its star eczema treatment to boost earnings, in the face of pressure to come up with a COVID-19 vaccine to tackle the global pandemic. The drugmaker said on Friday earnings per share would grow further this year after it posted stronger-than-expected fourth quarter results. Sanofi and Britain's GlaxoSmithKline stunned investors in December last year by warning a traditional, protein-based COVID-19 vaccine they are developing showed an insufficient immune response in older people, delaying its launch towards the end of 2021.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.